Winners, losers, and in-betweeners: How pharma companies stacked up in the Covid-19 vaccine race

In the early stages of the race to develop Covid-19 vaccines, it wasn’t clear how many would work, which manufacturers would score successes, or which projects would fall by the wayside.

Now, just a few days past the first anniversary of the start of Moderna’s Phase 1 trial — the first to begin in the United States — we have a much clearer picture of the Covid vaccine landscape.

Indeed, the focus is now sharp enough to start to call out some early winners and early losers. The fate of some development work remains uncertain, but one thing can be stated with conviction — the world already has a number of highly protective Covid vaccines and may have several more, both in first-generation iterations and in next-generation products aimed at troublesome variants.  

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In